The name is the button.

An agent writes the code now, and a human thumb hovers over Accept all a hundred times a day. The honest question of this decade is what, exactly, you just accepted. So I read the diff.

Eight years as a backend engineer in Stockholm, back in Tokyo since 2023, and I still ship something small most nights, usually badly. My one rule: the only real review of a model is the thing you built with it. That is why there is no leaderboard on this site.

Around a hundred and forty sources come through — the labs' own posts, the papers, the tools, the runtimes and languages nobody is watching yet, the chip under the demo, and the newsletters people actually forward. What is moving gets counted so the week reads at a glance, and every few days I explain one mechanism in plain words.

A story here is a headline, a short excerpt, one image and the link to whoever wrote it. We never reproduce the post; the images belong to their authors. A post written in Japanese appears in Japanese, exactly as it was published, and the link goes to the original.

— Yuki Halvorsen, Tokyo

← Accept All Archive

Tech in AsiaAsia

OpenAI acquires biopharma software platform Orchestra Bio

10.21

Per OpenAI, drug development takes about 10 to 15 years on average from discovery to US approval.

Funding & deals

Read at Tech in Asia ↗

One letter a week, starting soon.

Latest

OpenAI acquires biopharma software platform Orchestra Bio

Related

AsiaSpark Capital leads $325m round for AI aviation startup ASI Tech in Asia

AsiaSalesforce to acquire marketing software firm for $5.6b Tech in Asia

AsiaGeneral Catalyst backs Otter.ai with $320m in funding Tech in Asia

AsiaDayOne considers delaying, shrinking planned US IPO Tech in Asia

AsiaNvidia-backed AI planning startup Pigment raises $250m Tech in Asia

AsiaNvidia CEO to deliver keynote speech in Berlin as his firm faces investor scrutiny over AI SCMP Tech